Multiple myeloma (MM) is a mature B-cell neoplasm characterized by the presence of ≥10% clonal plasma cells in the bone marrow and evidence of end-organ damage, such as hypercalcemia, renal insufficiency, anemia, one or more osteolytic lesions on skeletal radiography, computed tomography (CT), or positron emission tomography-computed tomography (PET-CT); or myeloma-defining biomarkers (clonal bone marrow plasma cell percentage ≥60%, serum free light chain ratio ≥100, or two or more lesions of at least 5 mm on whole-body magnetic resonance imaging (MRI)) [1]. Here, TNFSF14 is linked to plasma cell myeloma.